What controversy? Eli Lilly plots Alzheimer's BLA filing later this year as FDA taps more anti-amyloid drugs as breakthroughs
The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.
Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.